Opioid dependence.
2gether Foundation Trust, Gloucester, United Kingdom.
K Thyarappa
KT
Praveen
Fergus
F
Law
Jacinta
J
O'Shea
Jan
J
Melichar
D002047:Buprenorphine / Q000008:administration & dosage; D003000:Clonidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D019317:Evidence-Based Medicine; D006801:Humans; D008658:Inactivation, Metabolic; D008691:Methadone / Q000008:administration & dosage; D009270:Naloxone / Q000008:administration & dosage; D009271:Naltrexone / Q000008:administration & dosage; D009292:Narcotic Antagonists / Q000008:administration & dosage*; D009294:Narcotics / Q000008:administration & dosage*; D058850:Opiate Substitution Treatment / Q000379:methods; D009293:Opioid-Related Disorders / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D011379:Prognosis; D012307:Risk Factors; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control*; D013997:Time Factors
D009292:Narcotic Antagonists; D009294:Narcotics; D009270:Naloxone; D002047:Buprenorphine; D009271:Naltrexone; D003000:Clonidine; D008691:Methadone; C025655:lofexidine